Leflon (Leflunomide)

Leflunomide blocks the enzyme dihydroorotate dehydrogenase, which is required for de novo pyrimidine synthesis. By limiting pyrimidine production, the drug suppresses the proliferation of activated lymphocytes, thereby decreasing the immune‑driven inflammation that underlies rheumatoid and psoriatic arthritis.

The specific dosage of Leflon is determined by the prescribing clinician based on the patient’s condition, response, and tolerability. Healthcare professionals set the initial dose and any subsequent adjustments, following current clinical guidelines and individual patient needs.

Leflon is classified as Pregnancy Category X, meaning it is contraindicated during pregnancy because it can cause fetal harm, including birth defects. It is also not recommended for breastfeeding mothers, as leflunomide can be excreted in breast milk and may affect the infant.

To order Leflon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

The primary alternative to leflunomide is methotrexate, another disease‑modifying antirheumatic drug (DMARD). While both reduce disease activity, leflunomide is taken orally once daily and may have a different safety profile, especially regarding liver toxicity and teratogenic risk. Choice between them depends on patient tolerance, comorbidities, and physician judgment.

Leflon should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture and direct light. Keep it out of reach of children and do not use if the packaging is damaged or the tablet appears discolored.

Leflon is administered orally, usually as a tablet taken with or without food, according to the prescriber’s instructions. Patients should swallow the tablet whole with a full glass of water and follow any specific guidance regarding timing or dose adjustments.

The most serious risks include severe liver injury, bone marrow suppression (which can lead to low blood counts), and interstitial lung disease. Patients should promptly report symptoms such as jaundice, unusual bruising or bleeding, persistent cough, or shortness of breath to their healthcare provider.

Leflon should not be used by pregnant women, individuals with severe liver disease, or patients with known hypersensitivity to leflunomide. It is also contraindicated in patients with active, uncontrolled infections and should be used with caution in those with pre‑existing lung conditions.